Graphite Bio Past Earnings Performance
Past criteria checks 0/6
Graphite Bio's earnings have been declining at an average annual rate of -25%, while the Biotechs industry saw earnings growing at 15.3% annually.
Key information
-25.0%
Earnings growth rate
98.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -67.9% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Sep 20
We're Hopeful That Graphite Bio (NASDAQ:GRPH) Will Use Its Cash Wisely
Jun 02Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Feb 01Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation
Oct 05Graphite Bio doses first patient with GPH101 for sickle cell disease
Aug 11Will Graphite Bio (NASDAQ:GRPH) Spend Its Cash Wisely?
Jun 22Graphite Bio: Selling For Much Less Than Net Cash
May 25Graphite Bio: An Important Stock To Track In The Gene Editing Space
Nov 18Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans
Sep 25Graphite Bio: Assessing Prospects Amid Doubts Raised On Safety Of Crispr
Aug 30Revenue & Expenses BreakdownBeta
How Graphite Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -125 | 41 | 32 |
| 30 Sep 23 | 0 | -126 | 35 | 51 |
| 30 Jun 23 | 0 | -129 | 31 | 67 |
| 31 Mar 23 | 0 | -99 | 33 | 71 |
| 31 Dec 22 | 0 | -101 | 33 | 73 |
| 30 Sep 22 | 0 | -95 | 32 | 66 |
| 30 Jun 22 | 0 | -85 | 30 | 56 |
| 31 Mar 22 | 0 | -77 | 26 | 51 |
| 31 Dec 21 | 0 | -71 | 23 | 38 |
| 30 Sep 21 | 0 | -115 | 17 | 33 |
| 30 Jun 21 | 0 | -104 | 12 | 27 |
| 31 Mar 21 | 0 | -88 | 8 | 15 |
| 31 Dec 20 | 0 | -68 | 4 | 9 |
Quality Earnings: GRPH is currently unprofitable.
Growing Profit Margin: GRPH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRPH is unprofitable, and losses have increased over the past 5 years at a rate of 25% per year.
Accelerating Growth: Unable to compare GRPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: GRPH has a negative Return on Equity (-67.9%), as it is currently unprofitable.